Details of the Drug

General Information of Drug (ID: DMTTW9V)

Drug Name

NBI-921352

Synonyms

Zandatrigine; XEN901; NBI-921352; XEN-901; SV2WPA4R4J; UNII-SV2WPA4R4J; 2154406-04-7; Benzenesulfonamide, 2-fluoro-5-methyl-4-(methyl((3S)-1-(phenylmethyl)-3-pyrrolidinyl)amino)-N-4-thiazolyl-; Benzenesulfonamide, 2-fluoro-5-methyl-4-[methyl[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]-N-4-thiazolyl-; zandatrigine [INN]; CHEMBL4650313; SCHEMBL19613237; GTPL11734; BDBM470680; (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide formate; NBI921352; US10815229, Example 101; AKOS040757364; MS-28458; HY-147423; CS-0564178; F84519; 4-[[(3S)-1-benzylpyrrolidin-3-yl]-methylamino]-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzenesulfonamide; 4-{[(3S)-1-benzylpyrrolidin-3-yl](methyl)amino}-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzene-1-sulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Epileptic encephalopathy	8A62	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C22H25FN4O2S2
Canonical SMILES: CC1=CC(=C(C=C1N(C)C2CCN(C2)CC3=CC=CC=C3)F)S(=O)(=O)NC4=CSC=N4
InChI: InChI=1S/C22H25FN4O2S2/c1-16-10-21(31(28,29)25-22-14-30-15-24-22)19(23)11-20(16)26(2)18-8-9-27(13-18)12-17-6-4-3-5-7-17/h3-7,10-11,14-15,18,25H,8-9,12-13H2,1-2H3/t18-/m0/s1
InChIKey: UCSHINHOAVARGQ-SFHVURJKSA-N

Cross-matching ID

PubChem CID: 132141687
TTD ID: DMT4U6

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.6 (SCN8A)	TT54ERL	SCN8A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05226780) A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Neurocrine Biosciences